Despite reports of NCS‐1 being associated with therapeutic response to paclitaxel (Moore et al., 2017; Moore et al., 2018), it remains unknown if this is associated with changes in Ca2+ signaling in breast cancer cells. This evidence concerns the gene NCS1 and breast cancer.